TABLE 7.
Most common eye- and skin-related adverse events (≥2% in either treatment group) reported by race through the end of treatment in the six pooled studies
| ADVERSE EVENT, N (%) | OVERALL | CAUCASIAN | NON-CAUCASIAN | AFRICAN AMERICAN | ASIAN | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| BIM 0.03% (n=680) | VEH (n=379) | BIM 0.03% (n=444) | VEH (n=190) | BIM 0.03% (n=236) | VEH (n=189) | BIM 0.03% (n=75) | VEH (n=53) | BIM 0.03% (n=135) | VEH (n=123) | |
| Overall (all categories) | 322 (47.4) | 130 (34.3) | 208 (46.8) | 59 (31.1) | 114 (48.3) | 71 (37.6) | 39 (52.0) | 16 (30.2) | 62 (45.9) | 49 (39.8) |
| Conjunctival hyperemia | 43 (6.3) | 5 (1.3) | 29 (6.5) | 1 (0.5) | 14 (5.9) | 4 (2.1) | 7 (9.3) | 2 (3.8) | 6 (4.4) | 1 (0.8) |
| Eyelids pruritus | 23 (3.4) | 8 (2.1) | 11 (2.5) | 4 (2.1) | 12 (5.1) | 4 (2.1) | 9 (12.0) | 4 (7.5) | 2 (1.5) | 0 |
| Erythema of eyelid | 22 (3.2) | 3 (0.8) | 16 (3.6) | 2 (1.1) | 6 (2.5) | 1 (0.5) | 2 (2.7) | 0 | 1 (0.7) | 0 |
| Blepharal pigmentation | 23 (3.4) | 2 (0.5) | 4 (0.9) | 0 (0.0) | 19 (8.1) | 2 (1.1) | 9 (12.0) | 0 | 9 (6.7) | 2 (1.6) |
| Punctate keratitis | 22 (3.2) | 6 (1.6) | 17 (3.8) | 4 (2.1) | 5 (2.1) | 2 (1.1) | 2 (2.7) | 1 (1.9) | 3 (2.2) | 1 (0.8) |
| Eye pruritus | 15 (2.2) | 3 (0.8) | 10 (2.3) | 2 (1.1) | 5 (2.1) | 1 (0.5) | 3 (4.0) | 0 | 2 (1.5) | 1 (0.8) |
| Dry eye | 14 (2.1) | 3 (0.8) | 8 (1.8) | 2 (1.1) | 6 (2.5) | 1 (0.5) | 3 (4.0) | 0 | 3 (2.2) | 1 (0.8) |
| Eye discharge | 4 (0.6) | 2 (0.5) | 0 | 0 | 3 (1.3) | 0 | 0 | 0 | 3 (2.2) | 0 |
| Skin hyperpigmentation | 4 (0.6) | 0 | 0 | 0 | 4 (1.7) | 0 | 4 (5.3) | 0 | 0 | 0 |
| Radiation skin injury | 8 (1.2) | 2 (0.5) | 2 (0.5) | 0 | 6 (2.5) | 2 (1.1) | 0 | 0 | 4 (3.0) | 2 (1.6) |
BIM=bimatoprost; URT=upper respiratory tract; VEH=vehicle